v3.25.3
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Oct. 31, 2025
Oct. 31, 2024
Operating expenses:    
Research and development expenses $ 6,683,643 $ 3,665,341
General and administrative expenses 1,639,300 1,487,491
Total operating expenses 8,322,943 5,152,832
Operating loss (8,322,943) (5,152,832)
Financial income, net 158,646 11,714
Change in fair value of the warrant liability (69,201) (616,643)
Share of loss on equity investment (44,830) (71,515)
Net loss for the period (8,278,328) (5,829,276)
Net loss attributable to non-controlling interest (80,763) (27,101)
Net loss for the period attributable to BriaCell $ (8,197,565) $ (5,802,175)
Net loss per share attributable to BriaCell - basic $ (4.35) $ (32.67)
Net loss per share attributable to BriaCell - diluted $ (4.35) $ (32.67)
Weighted average number of shares used in computing net basic loss per share of common stock 1,883,906 177,606
Weighted average number of shares used in computing net diluted loss per share of common stock 1,883,906 177,606